Efficacy Of Lipid-lowering And Anti-inflammatory Effects Of Statins Sequential Therapy In Coronary Heart Disease Patients(CHD) Undergoing Elective PCI

Objective:To assess the influence and safety of early atorvastatinsequential therapy in coronary heart disease (CHD) patients underdoing electivepercutaneous coronary intervention on selected indicators of inflammation andserum lipids.Method:a total of88CHD patients who got ready to receive the electivepercutaneous coronary intervention(PCI) were divided in two groups at random:Thesequential dose group was called group A(atorvatatin80mg as loading dose,40mg/dfor1month and20mg/d subsequently,n=43),and the ordinary dose group wascalled group B(atorvatatin20mg/d,n=45). During the follow-up times, bloodwere taken at baseline,3days,1month,3months and6months formyeloperoxidase(MPO),matrix metalloproteinase-9(MMP-9), interleukin-18（IL-18）,creactive potein(CRP)，serum lipids,serum alanine aminotransferase(ALT),glutamyl endopeptidase(GGT),creatine kinase(CK) and so on.Main adverse cardiacevents and adverse effects were also analyzed.Result:Compared with the baseline,the level of low-densitylipoprotein-cholesterol(LDL-C) and total cholesterol(TC) was significantlydecreased in both two groups after treatment (P＜0.05).The LDL-C and TC atthe two groups were all observably decreased after treatment, and the decreasing degree of LDL-C and TC levels at3days had significant differencesbetween two groups（P＜0.05）.The decreasing degree of LDL-C at1monthbetween the two groups also had significant differences（P＜0.05.The changes inLDL—C and TC level were also significantly different between the two groups at3and6months（P＜0.05）.While TG and HDL-C remained unchanged（P＞0.05）.MMP-9, MPO, IL-18and CRP were significant reduced post medicationcompared to pre-treatment medication. There were significant differences in the twogroups after therapy than before therapy(P＜0.05).MPO was decreased significantlyin group A after treatment （P＜0.05）And the same differences in group B werealso significant（P＜0.05）. MPO post medication between the2groups were notsignificantly different（P＞0.05）. MMP-9had significant differences thereaftergroup A compared to group B.MMP-9also had significantly reduced postmedication compared to pre-treatment medication in the two groups.IL-18andCRP were also decreased significantly after treatment in both two groups（P＜0.05）.The adverse effects had no significant differences between the2groups(P＞0.05).Conclution:The atorvastatin sequentail theapy in CHD patients undergoingelective percutaneous coronary intervention could decrease serum lipidssignificantly.Pretreatment with atorvastatin for patients undergoing PCI cloudinhibit inflammation，and the sequential therapy of atorvastatin might stabilizethe plaque.The MACE and adverse effects were similar between the groups.